6033 related articles for article (PubMed ID: 3619974)
1. Tumor inhibition by titanocene complexes. Activity against B16 melanoma and colon 38 carcinoma.
Köpf-Maier P; Köpf H
Arzneimittelforschung; 1987 May; 37(5):532-4. PubMed ID: 3619974
[TBL] [Abstract][Full Text] [Related]
2. Tumor inhibition by titanocene complexes: activity against sarcoma 180.
Köpf-Maier P; Preiss F; Marx T; Klapötke T; Köpf H
Anticancer Res; 1986; 6(1):33-7. PubMed ID: 3954328
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of an ionic titanocene tetrachloroferrate derivative against some solid experimental tumors.
Köpf-Maier P; Klapötke T
Arzneimittelforschung; 1989 Apr; 39(4):488-90. PubMed ID: 2751735
[TBL] [Abstract][Full Text] [Related]
4. Antitumor metallocenes: new developments and toxicologic features.
Köpf-Maier P; Köpf H
Anticancer Res; 1986; 6(2):227-33. PubMed ID: 3707060
[TBL] [Abstract][Full Text] [Related]
5. Tumor inhibition by ferricenium complexes. Activity against some solid experimental tumors.
Köpf-Maier P; Klapötke T
Arzneimittelforschung; 1989 Mar; 39(3):369-71. PubMed ID: 2757661
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma.
Köpf-Maier P
Anticancer Res; 1999; 19(1A):493-504. PubMed ID: 10226588
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH
Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436
[TBL] [Abstract][Full Text] [Related]
8. Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion.
Bernacki RJ; Oberman EJ; Seweryniak KE; Atwood A; Bergeron RJ; Porter CW
Clin Cancer Res; 1995 Aug; 1(8):847-57. PubMed ID: 9816054
[TBL] [Abstract][Full Text] [Related]
9. Ionic titanocene complexes: a new type of antitumor agent.
Köpf-Maier P; Neuse E; Klapötke T; Köpf H
Cancer Chemother Pharmacol; 1989; 24(1):23-7. PubMed ID: 2720888
[TBL] [Abstract][Full Text] [Related]
10. Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour.
Valadares MC; Ramos AL; Rehmann FJ; Sweeney NJ; Strohfeldt K; Tacke M; Queiroz ML
Eur J Pharmacol; 2006 Mar; 534(1-3):264-70. PubMed ID: 16513106
[TBL] [Abstract][Full Text] [Related]
11. Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo.
Gutman M; Szold A; Ravid A; Lazauskas T; Merimsky O; Klausner JM
Anticancer Res; 1996; 16(6B):3673-7. PubMed ID: 9042240
[TBL] [Abstract][Full Text] [Related]
12. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors.
Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Malivet V; Chacun C; Jan M; Tillequin F; Michel S; Koch M; Pfeiffer B; Atassi G; Hickman J; Pierré A
Clin Cancer Res; 2001 Aug; 7(8):2573-80. PubMed ID: 11489841
[TBL] [Abstract][Full Text] [Related]
13. Ascorbic acid and 6-deoxy-6-chloro-ascorbic acid: potential anticancer drugs.
Osmak M; Kovacek I; Ljubenkov I; Spaventi R; Eckert-Maksić M
Neoplasma; 1997; 44(2):101-7. PubMed ID: 9201289
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the growth of various human and mouse tumor cells by 1,15-bis(ethylamino)-4,8,12-triazapentadecane.
Igarashi K; Koga K; He Y; Shimogori T; Ekimoto H; Kashiwagi K; Shirahata A
Cancer Res; 1995 Jun; 55(12):2615-9. PubMed ID: 7780977
[TBL] [Abstract][Full Text] [Related]
15. 4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent.
Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y
Cancer Res; 1982 Apr; 42(4):1462-7. PubMed ID: 7060020
[TBL] [Abstract][Full Text] [Related]
16. Experimental antitumor activity and toxicity of the selected triazolo- and imidazoacridinones.
Kuśnierczyk H; Chołody WM; Paradziej-Lukowicz J; Radzikowski C; Konopa J
Arch Immunol Ther Exp (Warsz); 1994; 42(5-6):415-23. PubMed ID: 8572901
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of antitumor and antimetastatic activities of alpha-difluoromethylornithine by interferon inducers.
Sunkara PS; Prakash NJ; Rosenberger AL; Hagan AC; Lachmann PJ; Mayer GD
Cancer Res; 1984 Jul; 44(7):2799-802. PubMed ID: 6426786
[TBL] [Abstract][Full Text] [Related]
18. Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors.
Dexter DL; Hesson DP; Ardecky RJ; Rao GV; Tippett DL; Dusak BA; Paull KD; Plowman J; DeLarco BM; Narayanan VL
Cancer Res; 1985 Nov; 45(11 Pt 1):5563-8. PubMed ID: 4053030
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of dichlorobis(1-phenylbutane-1,3-dionato)titanium (IV) and budotitane. Two representatives of the new class of antitumor-active bis-beta-diketonato metal complexes.
Keppler BK; Schmähl D
Arzneimittelforschung; 1986 Dec; 36(12):1822-8. PubMed ID: 3566844
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
